Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Beam Therapeutics reported a patient death in a gene editing trial for sickle cell disease, overshadowing otherwise positive data. Beam-101 was found to be competitive with approved treatments, highlighting the need for less-toxic preconditioning treatments. Sana Biotechnology is planning workforce cuts to reprioritize focus on its type 1 diabetes program and extend i...